ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biophar...
Ascendiant Capital Markets dropped their target price on Outlook Therapeutics from $24.00 to $21.00 ...
OTLK has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 4 analysts rating...
Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Analysts at Brookline Capital Management in...